To explore the clinical efficacy of ultrasound-guided injection of botulinum toxin type A in the treatment of low back myofascial pain syndrome.

Prospective collection of 78 patients with lower back myofascial pain syndrome in our hospital from January 2020 to June 2024, including 46 males and 32 females,aged(48.04±4.95) years. they were randomly divided into two groups by the digital table method. The control group was given trigger point block therapy, and the observation group was treated with trigger point botulinum toxin type A injection under ultrasound guidance. The McGill Pain Questionnaire (MPQ) before and after treatment was compared between the two groups. Serum levels of inflammatory factors and pain-causing factors were detected before and after treatment. The comprehensive clinical efficacy was assessed.

78 patients were followed up for (30.5±2.0) days. After treatment, the MPQ questionnaire pain classification (pain rating indexPRI), analogy score (visual analogue scaleVAS), and intensity (present pain index PPI) scores of the two groups of patients decreased significantly, the three scores of the observation group were 2.03±0.24 1.98±0.28 1.24±0.12 and the control group were 2.84±0.30 2.59±0.35 1.66±0.17, which were significantly lower than those of the control group (P<0.05). After treatment, the levels of serum interleukin 6 (IL-6), tumor necrosis factor (TNF-α) and other inflammatory factors, as well as prostaglandin E2 (PGE2), cyclooxygenase 2 (COX-2), etc. caused pain in the two groups. The factor level was significantly reduced, the four indexes in the observation group were 39.34±5.34 2.02±0.48 9.42±1.07 29.43±4.03. The control group was 48.83±7.20 2.69±0.54 12.66±2.14 37.68±5.15, which were significantly lower than the control group (P<0.05). The total effectiverate was 92.31% in the observation group and 74.36% in the control group, which was significantly higher than that in the control group (P<0.05).

Trigger point type A botulinum toxin injection under ultrasound guidance has a significant analgesic effect on Lumbodorsal myofascial pain syndrome which can reduce the levels of inflammatory factors and endogenous pain-causing factors.